Mesoblast Limited

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that the United States Patent and Trade Mark Office (USPTO) has granted a key patent, US Patent 7,399,632, through to at least the year 2019.

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB; USOTC: MBLTY), today announced highly significant preclinical trial results of the adult stem cell technology platform for the treatment of eye diseases associated with abnormal blood vessels. These diseases include diabetic retinopathy and age-related macular degeneration (AMD), the leading causes of blindness in the western world.

Mesoblast Limited's (ASX:MSB; USOTC:MBLTY) "Off the Shelf" adult stem cells heal bodies without rejection or ethical issues, now about 3 years from commercialisation and trading near its lows.

According to the June edition of Bioshares, Mesoblast Limited (ASX:MSB)(USOTC:MBLTY)(PINK:MEOBF) has made exceptionally good progress with its adult stem cell therapy in several applications.

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(USOTC:MBLTY)(PINK:MEOBF), today announced that the United States Food and Drug Administration (US FDA) had cleared an Investigational New Drug (IND) submission by its US-based sister company, Angioblast Systems Inc., to commence a Phase 2 trial of the stem cell platform technology for treating patients with congestive heart failure.

Mesoblast Limited's (ASX: MSB)(PINK:MBLTY) record of accomplishment since its ASX listing in December 2004 has been first rate. Within only 3.5 years, the Company has established itself as a world leader in the development of innovative biological products in the emerging and potentially highly lucrative regenerative medicine field.

Mesoblast Limited (ASX:MSB)(US:MBLTY) Announce Research Note By ABN AMRO

Australia's adult stem cell company, Mesoblast Limited (ASX: MSB; USOTC: MBLTY), today announced successful long-term results in its osteoarthritis preclinical trials. A single injection of its proprietary allogeneic, or "off-the-shelf", adult stem cells into arthritic knees provided sustained protection against cartilage destruction and degeneration for up to nine months.

Australia's adult stem cell company, Mesoblast Limited (ASX: MSB)(USOTC: MBLTY), today announced that it will accelerate its clinical trial timetable towards commencement of a Phase 3 trial in spinal fusion by mid 2009 following encouraging preliminary safety data from its ongoing Phase 2 clinical trial.

Doctors at Houston's Texas Heart Institute held a press conference last Saturday (AEST) to provide an update on the ongoing multi-centre Phase 2 clinical trial of the proprietary mesenchymal precursor cell (MPC) technology in patients with heart attacks.